The evaluation of the adequacy of the super-high-priced Kymriah's benefit is approaching insurance coverage. This is because the agenda to expand the health insurance standards for Kymriah, a treatment for acute lymphocytic leukemia and lymphoma CAR-T, and Keytruda, a non-small cell lung cancer immuno-cancer drug, passed side by side at the HIRA meeting on the 13th.

Until now, the biggest obstacle when it was decisively blocked by cost-effectiveness in the process of reimbursement for high-priced drugs was the discussion process of the Pharmacist Evaluation Committee or the Cancer Disease Review Committee. Whenever the reimbursement priority and adequacy were discussed, the effect and necessity were rec